Why It Matters

Acesso Biologics’ is hiring Holland & Knight to move from primarily regulatory advocacy to direct legislative engagement. This strategic move comes as Congress actively considers the Skin Substitute Access and Payment Reform Act of 2025 (S.2561), legislation that could reshape Medicare payment structures for wound care products.

By the Numbers

Acesso Biologics has spent $370,000 on federal lobbying since entering the advocacy arena in 2024. The company previously worked with Michael Best Strategies LLC ($240,000) and McManus Group ($130,000) before engaging Holland & Knight LLP on June 1, 2024.

Acesso’s new lobbyists bring directly relevant expertise: Miranda A. Franco has represented the Alliance for Regenerative Medicine and ConvaTec Advanced Tissue Technologies on Medicare wound care coverage, while Jordan K. Brossi brings five years of congressional staff experience, including work as Health Policy Adviser to Rep. Anna Eshoo, whose committee has primary jurisdiction over Medicare Part B.

The Agenda

Acesso Biologics is lobbying specifically on the Skin Substitute Access and Payment Reform Act of 2025 (S.2561) and Medicare coverage issues for wound care products. The bipartisan legislation would reform how Medicare pays for skin substitute products by establishing volume-weighted average payment limits effective January 1, 2026.

The company’s advocacy joins a crowded field including Organogenesis Inc., VIVEX Biologics Inc., and others, all focused on influencing the same legislative and regulatory battlegrounds.

Broader Context

Congress is actively debating how to overhaul Medicare’s payment system for skin substitutes. The Skin Substitute Access and Payment Reform Act of 2025 (S.2561) and its House companion H.R.5768 have bipartisan support from sponsors including Sen. Bill Cassidy (R-LA) and Rep. Buddy Carter (R-GA).

Meanwhile, CMS proposed reclassifying skin substitutes as incident-to supplies rather than biologicals, a change that could reduce reimbursement by approximately 90 percent. The industry faces significant pressure as Medicare spending on skin substitutes has surged dramatically, with concerns about pricing practices and questionable billing patterns.

Competitive Landscape

Acesso Biologics faces significant industry competition on S.2561. Major competitors actively lobbying the same legislation include Organogenesis Inc., BioWound Solutions LLC, VIVEX Biologics Inc., and Royal Biologics Inc.. The shared focus indicates S.2561 is the central policy battleground for the advanced wound care industry.

Spot something wrong? Report an issue with this article